141 related articles for article (PubMed ID: 32572469)
1. Multiple eruptive dermatofibromas aggravated by mycophenolate mofetil and pirfenidone in a patient with systemic sclerosis.
Wang R; Li G; Nong L; Wang M
Rheumatology (Oxford); 2020 Dec; 59(12):4000-4001. PubMed ID: 32572469
[No Abstract] [Full Text] [Related]
2. An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Khanna D; Albera C; Fischer A; Khalidi N; Raghu G; Chung L; Chen D; Schiopu E; Tagliaferri M; Seibold JR; Gorina E
J Rheumatol; 2016 Sep; 43(9):1672-9. PubMed ID: 27370878
[TBL] [Abstract][Full Text] [Related]
3. Multiple Eruptive Dermatofibromas in a Patient Treated With Brentuximab Vedotin.
Giavedoni P; Combalia A; Pigem R; Mascaró JM
Actas Dermosifiliogr (Engl Ed); 2019 Jun; 110(5):419-420. PubMed ID: 30717880
[No Abstract] [Full Text] [Related]
4. Mycophenolate mofetil-induced colitis in a patient with systemic sclerosis.
Moroncini G; Benfaremo D; Mandolesi A; Gabrielli A
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29776943
[TBL] [Abstract][Full Text] [Related]
5. A new therapy for systemic sclerosis-associated interstitial lung disease.
Kondoh Y
Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
[No Abstract] [Full Text] [Related]
6. Mycophenolate mofetil as a therapeutic agent for interstitial lung diseases in systemic sclerosis.
Ueda T; Sakagami T; Kikuchi T; Takada T
Respir Investig; 2018 Jan; 56(1):14-20. PubMed ID: 29325675
[TBL] [Abstract][Full Text] [Related]
7. Multiple eruptive plaque-like dermatofibromas during anti-TNFα treatment.
Caldarola G; Bisceglia M; Pellicano R
Int J Dermatol; 2013 May; 52(5):638-41. PubMed ID: 22804251
[No Abstract] [Full Text] [Related]
8. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.
Tashkin DP; Roth MD; Clements PJ; Furst DE; Khanna D; Kleerup EC; Goldin J; Arriola E; Volkmann ER; Kafaja S; Silver R; Steen V; Strange C; Wise R; Wigley F; Mayes M; Riley DJ; Hussain S; Assassi S; Hsu VM; Patel B; Phillips K; Martinez F; Golden J; Connolly MK; Varga J; Dematte J; Hinchcliff ME; Fischer A; Swigris J; Meehan R; Theodore A; Simms R; Volkov S; Schraufnagel DE; Scholand MB; Frech T; Molitor JA; Highland K; Read CA; Fritzler MJ; Kim GHJ; Tseng CH; Elashoff RM;
Lancet Respir Med; 2016 Sep; 4(9):708-719. PubMed ID: 27469583
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.
Shenoy PD; Bavaliya M; Sashidharan S; Nalianda K; Sreenath S
Arthritis Res Ther; 2016 Jun; 18(1):123. PubMed ID: 27255492
[TBL] [Abstract][Full Text] [Related]
10. Eruptive dermatofibromas and immunosuppression.
Gualandri L; Betti R; Cerri A; Pazzini C; Crosti C
Eur J Dermatol; 1999; 9(1):45-7. PubMed ID: 9920988
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil is an effective and safe option for the management of systemic sclerosis-associated interstitial lung disease: results from the Australian Scleroderma Cohort Study.
Owen C; Ngian GS; Elford K; Moore O; Stevens W; Nikpour M; Rabusa C; Proudman S; Roddy J; Zochling J; Hill C; Sturgess A; Tymms K; Youssef P; Sahhar J
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):170-176. PubMed ID: 27049330
[TBL] [Abstract][Full Text] [Related]
12. Multiple eruptive dermatofibromas in a patient with dermatomyositis taking prednisolone and methotrexate.
Huang PY; Chu CY; Hsiao CH
J Am Acad Dermatol; 2007 Nov; 57(5 Suppl):S81-4. PubMed ID: 17097372
[TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease.
Gkiouras K; Grammatikopoulou MG; Simopoulou T; Daniil Z; Bogdanos DP
Clin Rheumatol; 2021 Aug; 40(8):3379-3380. PubMed ID: 34213671
[No Abstract] [Full Text] [Related]
14. Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug.
Saketkoo LA; Espinoza LR
Arch Intern Med; 2008 Aug; 168(15):1718-9. PubMed ID: 18695091
[No Abstract] [Full Text] [Related]
15. Novel Therapeutic Approaches for Pulmonary Manifestations of Systemic Sclerosis.
Lui JK; Bosch NA; Gillmeyer KR; Reardon CC
Am J Respir Crit Care Med; 2020 Sep; 202(6):878-880. PubMed ID: 32574505
[No Abstract] [Full Text] [Related]
16. David against Goliath: may we target and defeat interstitial lung disease in systemic sclerosis?
Miniati I; Conforti ML; Guiducci S; Matucci Cerinic M
Clin Exp Rheumatol; 2007; 25(2):169-71. PubMed ID: 17543137
[No Abstract] [Full Text] [Related]
17. Multiple eruptive dermatofibromas in a patient receiving efalizumab.
Santos-Juanes J; Coto-Segura P; Mallo S; Galache C; Soto J
Dermatology; 2008; 216(4):363. PubMed ID: 18292655
[No Abstract] [Full Text] [Related]
18. [Unusual cutaneous angiofibromatosis following gold therapy of primary chronic polyarthritis].
Herbst WM; Hornstein OP; Griessmeyer G
Hautarzt; 1989 Sep; 40(9):568-72. PubMed ID: 2572572
[TBL] [Abstract][Full Text] [Related]
19. Treatment Algorithms for Systemic Sclerosis According to Experts.
Fernández-Codina A; Walker KM; Pope JE;
Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.
Goldin JG; Kim GHJ; Tseng CH; Volkmann E; Furst D; Clements P; Brown M; Roth M; Khanna D; Tashkin DP
Ann Am Thorac Soc; 2018 Nov; 15(11):1286-1295. PubMed ID: 30265153
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
